Sarepta Therapeutics Announces Positive and Robust Expression and Biomarker Data from the First Three-Patient Cohort Dosed in the MYO-101 Gene Therapy Trial to Treat Limb-Girdle Muscular Dystrophy Typ
Go back to Sarepta Therapeutics Announces Positive and Robust Expression and Biomarker Data from the First Three-Patient Cohort Dosed in the MYO-101 Gene Therapy Trial to Treat Limb-Girdle Muscular Dystrophy Typ| SAREPTA THERAP (NASDAQ: SRPT) | Delayed: 22.20 +1.26 (6.02%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $20.94 | 52 Week High | $63.73 | |||
| Open | $20.81 | 52 Week Low | $8.00 | |||
| Day High | $23.22 | P/E | N/A | |||
| Day Low | $20.63 | EPS | $-5.69 | |||
| Volume | 2,809,981 | |||||
